Atreca announces corporate reorganization, to cut workforce by more than 25%
seekingalpha.com
business
2022-06-01 20:16:40

Jun. 01, 2022 4:16 PM ETAtreca, Inc. (BCEL)By: Anuron Mitra, SA News Editor Dilok Klaisataporn/iStock via Getty Images 
 Atreca (NASDAQ:BCEL) on Wednesday said it would cut its workforce by more than 25% and will continue to focus on its cancer therapies ATRC-101, ATRC-301 and its other preclinical assets.
The clinical-stage biotech said the corporate reorganization would extend its cash runway through 2023.
The San Carlos, Calif.-based company is on track to report data from its ATRC-101 and ATRC-301 programs in H2 2022.
